The Clinical Relevance of Urinary Soluble Fas (sFas) for Diagnosis of Bilharzial Bladder Cancer

SANAA EISSA, M.D.1; MENHA SWELLAM, Ph.D.2; CAMILIA ABDEL MALAK, Ph.D.3; MOHAMED NOSHI FAHIM, M.Sc.3; RASHA RASHEED FAKHR EL-DEEN, M.Sc.4; MOHAMED F. MOUSTAFA, Ph.D.4; ABEER IBRAHIM ABDEL FATTAH, Ph.D.5 and MOHAMED ESMAT, Ph.D.6

The Departments of Oncology, Diagnostic Unit, Medical Biochemistry, Faculty of Medicine, Shams University, Cairo, Egypt; Genetic Engineering and Biotechnology Division, Biochemistry, National Research Center, Gizza, Egypt; Biochemistry Division, Faculty of Science, Damietta University, Damietta, Egypt; Biochemistry, Faculty of Pharmacy, MUST University, Gizza, Egypt; Biochemistry, Faculty of Pharmacy (Girls), Il-Itzhar University, Cairo, Egypt; and Urology, Faculty of Medicine, Shams University, Cairo, Egypt

Abstract

Purpose: Fas/CD95, a membrane-bound type I protein, plays a key role in induction of apoptosis and in tumorigenesis. Authors adapted and evaluated measurement of urinary sFas using enzyme-linked immunosorbent assay and compared the results with voided urine cytology.

Material and Methods: Voided urine samples were provided from 203 individuals (120 bladder cancer [112 bilharzial]; 43 benign urologic disorders [20 bilharzial dysplastic lesions]; 40 healthy volunteers). Urine sediment was used for cytology and the supernatant for estimation of sFas by ELISA.

Results: Receiver operating characteristic curve (ROC) curve was used to determine the best cutoff value for urinary sFas. Positivity rates and mean rank levels for sFas showed significant difference among the three investigated groups (p<0.0001), and was related to bilharzial infection, pathological type, clinical stages and histological grades (p<0.01). The sensitivity of sFas for early detection of bladder cancer especially those with superficial and low grades tumors was superior to urine cytology, moreover, sensitivity of urine cytology was improved when combined with sFas.

Conclusion: Urinary sFas may be used as a novel non-invasive diagnostic marker for bilharzial bladder cancer patients. Further multicentric studies are warranted to corroborate these findings and to establish an optimal sFas cut-point.

Key Words: SFas — Bilharzial bladder cancer — Voided urine cytology.

Introduction

BLADDER cancer is a global problem, however the highest frequency of bladder cancer worldwide is observed in Egypt. This high incidence is believed to be due to endemic infestation by Schistosoma hematobium, which contributes to defining the characteristic pathology "Schistosoma-associated bladder cancer (SABC)" [ii or simply Bilharzial-associated bladder cancer (BBC). According to the registry of the National Cancer Institute, Cairo, 2002 [2], bilharzial-associated bladder cancer represents the commonest malignancy in all diagnosed cancer cases in Egypt.

To date, the gold standard for bladder cancer detection remains to be cystoscopy/biopsy of suspicious lesions. Not only this technique is invasive, but also 10% to 40% of malignancies may be undetected by this procedure [3]. On the other hand, urine cytology is known for its good specificity but poor sensitivity for early stages and low grades [4]. Thus, an array of urine markers that take advantage of exfoliated cells in the urine for detection of cell surface antigens, nuclear morphology, or gene expression have been studied in bladder cancer [5, 13] to improve the diagnostic ability of urine cytology and perhaps to reduce the need for frequent cystoscopies during follow-up, especially in those with low-risk disease [14]. While few markers have undergone clinical trials and have been approved for clinical use, most of them remain investigational and are undergoing further development and pre-clinical evaluation.

Abbreviations:
SFas : Soluble Fas.
ELISA : Enzyme linked immune assay.
ROC Curve : Receiver operating characteristic curve.
Detriment of apoptosis plays an important role in the development, growth and resistance of malignant tumors, and also influences the prognosis. As a member of TNF-family receptors, Fas (Apopt-1/CD95) is a cell surface protein that can induce apoptosis through its cytosolic tail after binding to its specific ligand, Fas Ligand (FasL). Fas is found in two forms, trans-membrane and soluble. The soluble form of Fas (sFas), which has five variants produced via alternative mRNA splicing, inhibits Fas-mediated apoptosis by neutralizing FasL or anti-Fas antibody [15]. Increased concentration of serum sFas has been reported in various neoplastic diseases, such as leukemia, lymphoma, and breast cancer. In bladder cancer patients, the association between increase in serum sFas and poor prognosis was indicated [16]. These findings suggest that cancer cells up-regulate or stimulate sFas production to protect themselves from Fas-mediated apoptosis [17].

This study was conducted to assess the diagnostic efficiency of sFas in voided urine samples especially those with bilharzial infestation in comparison to urine cytology. Moreover, it was planned to investigate its correlation with clinicopathological features of this malignancy.

Material and Methods

Study population:

A total of 203 individuals were enrolled in the present study. After obtaining informed consent, patients provided a single voided urine sample and a cytologic test for urine sediment was performed before cystoscopy. All patients underwent cystoscopy as the reference standard for detection of bladder carcinoma. Accordingly, the 163 patients included in the study were diagnosed into malignant and benign groups. The malignant group included 120 patients (mean age, 62 yrs ±11; range, 25-83 yrs). Of those patients, 44 were diagnosed by histopathology as transitional cell carcinoma (TCC), and 76 as squamous cell carcinoma (SCC). Tumor staging and grading were determined according to TNM and World Health Organization classification [18,19]. The benign group included 43 patients with benign urological diseases (mean age, 43 yrs ±15; range, 21-75 yrs). A group of 40 healthy volunteers (mean age, 39 yrs±8; range, 25-57 yrs) was recruited from the hospital laboratory staff as controls.

Collection of samples:

Sera (5ml) and voided urine (30-60 mL) samples were obtained from all individuals before they received any treatment and before they underwent surgery. Each urine sample was collected into an approved Urine Collection Cup that measures volume and sealed immediately and placed on ice then centrifuged for 15-20 min at 2500-4000 x g. The urinary sediment was washed twice with phosphate-buffered saline at pH 7.0. A portion of the pellet was used for cytologic and microscopic examinations [20].

Detection of schistosomiasis antibodies in serum:

The sera were used for detection of schistosomiasis antibodies by the indirect haemagglutination test, using the Cellognoste Schistosomiasis H kit (Dade Behring Marburg GmbH, Marburg, Germany) [21].

Assessment of human urinary sFAS:

sFas level was quantified by the ELISA sandwich method according to manufacturer's guidelines (Quantikine). Assay diluent was added to microtiter plates coated with a monoclonal antibody specific for sFas. Then, 100m1 of urine supernatants and standards were added to the wells and incubated for 2 hours at room temperature. After washing, sFas conjugant (polyclonal antibody against Fas conjugated to horseradish peroxidase) was added to wells and further incubation for 2 hours at room temperature was made. Second wash was done, then tetramethyl benzidine substrate was added and the plate was incubated for 30 min at room temperature in a dark place for color reaction. The reaction was then stopped by H2SO4. The optical density was measured at 450 nm/620 nm dual wave length using a spectrophotometer plate reader. A standard curve was created using computer software to determine sFas concentrations that are expressed in ng/mL. To control for the differences in urine concentration, the protein in urine was determined by Bradford’s method using bovine serum albumin as a calibrator. The sFas concentration was then expressed as ng/mg protein.

Statistical analysis:

The threshold value for optimal sensitivity and specificity of sFas was determined by Receiver Operating Characteristics (ROC) curve, which was constructed by calculating the true-positive fraction (sensitivity %) and false-positive fraction (100-specificity %) of the above-mentioned markers at several cut-off points. The ROC curve can be used to select the best cutoff for the diagnostic test that maximizes the sensitivity and minimizes the false-positive rate [23]. Univariate analyses were performed using a Chi-square test; the level of significance was determined to be less than 0.05. All
analyses were performed using Statistical Package for the Social Sciences software (SPSS Inc., Chicago, IL).

Results

A total of 203 participants were included in this study. One hundred and twenty were diagnosed with bladder cancer; 112 of them were bilharzial bladder cancer and the remaining (n=8) were non-bilharzial bladder cancer. Among the 43 patients diagnosed with benign urological diseases, 20 showed benign bilharzial lesions [12 with bilharzial dysplasia, 8 with bilharzial cystitis], and the rest (n=23) were non-bilharzial lesions (11 with renal stones, 7 with bladder polyp and 5 with pyelonephritis). All healthy volunteers (n=40) were non-bilharzial.

**ELISA performance characteristics:**

Pooled voided urine samples were used only for the validity experiments and to assure the reproducibility of the assays as follows:

A- We tested the precision of the urinary sFas by measuring the same sample pool for (a) six times in the same assay (intra-assay) and (b) for a five times in different days of the same or in different days (inter-assay). The results were reproducible as shown in (Table 1).

B- In experiment on the analytical recovery of the investigated urinary sFas we used three pools from urine supernatant 0.157, 0.428, and 1.448ng/mg protein for sFas, each sample was assayed in duplicates after addition of three different amounts of manufacturer- supplied kit calibrators (62.5, 250, 1000). The calculated recovery range is shown in (Table 1).

**Cutoff point for urinary sFas:**

The benign and healthy normal groups were combined in a non-malignant group and the best cutoff value for urinary sFas for the discrimination between non-malignant from malignant groups was calculated using ROC as 993.4 ng/mg protein which maximized the sum of the sensitivity and specificity at which highest predictive values are reached protein as shown in (Fig. 1).

**Relation between positivity rate of urinary sFas and clinicopathological factors:**

The relation between urinary sFas among the different clinicopathological factors in the malignant group revealed a significant difference to bilharziasis as 111 out of 117 (94%) bilharzial bladder cancer patients showed positive sFas (X²=17.8, p<0.0001), pathological types as all the SCC cases showed positive sFas (X²=5.31, p=0.021), clinical stages as 103 of early stage bladder cancer patients showed positive sFas (X²=7.7, p=0.005) and histological grades were all of low grade bladder cancer patients were positive sFas (X²=7.4, p=0.006).

**Combined sensitivity and specificity of urinary sFAS and urine cytology:**

Sensitivity and specificity for urinary sFAS and urine cytology as well as their combination were tested for detection of bladder cancer, superficial and low-grade tumors as shown in (Table 3). The sensitivity of urinary sFas was higher than urine cytology for detection of bladder cancer, superficial and low-grade tumors. Moreover, the sensitivity of urine cytology was improved when both were combined.

**Table (1): Performance of investigated urinary angiogenic markers.**

<table>
<thead>
<tr>
<th>Performance</th>
<th>Urinary sFas</th>
<th>Pool 1</th>
<th>Pool 2</th>
<th>Pool 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-assay (6):</td>
<td>Mean</td>
<td>0.157</td>
<td>0.428</td>
<td>1.448</td>
</tr>
<tr>
<td>SD</td>
<td>0.14</td>
<td>0.04</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>CV%</td>
<td>8.9</td>
<td>9.3</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Inter-assay (5):</td>
<td>Mean</td>
<td>0.157</td>
<td>0.428</td>
<td>1.448</td>
</tr>
<tr>
<td>SD</td>
<td>0.015</td>
<td>0.038</td>
<td>0.038</td>
<td></td>
</tr>
<tr>
<td>CV%</td>
<td>9.5</td>
<td>9.1</td>
<td>9.5</td>
<td></td>
</tr>
</tbody>
</table>

**Analytical recovery:**

<table>
<thead>
<tr>
<th>Basal</th>
<th>Added</th>
<th>Recovered</th>
<th>Recovery%</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.157</td>
<td>62.5</td>
<td>62.5</td>
<td>100</td>
</tr>
<tr>
<td>250</td>
<td>249</td>
<td>492</td>
<td>99.9</td>
</tr>
<tr>
<td>999</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
</tr>
<tr>
<td>99.9</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>
Table (2): Positivity rates of sFas and urine cytology among different investigated groups.

<table>
<thead>
<tr>
<th>sFas (ng/mg protein)</th>
<th>Control (n=40)</th>
<th>Total</th>
<th>Bilharzial status</th>
<th>Malignant (n=120)</th>
<th>Total</th>
<th>Bilharzial status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean rank a</td>
<td>30.12</td>
<td>55.81</td>
<td>23.4</td>
<td>26.2</td>
<td>142.51</td>
<td>66.8</td>
</tr>
<tr>
<td>993.4 ng/mg protein b</td>
<td>0 (0%)</td>
<td>9 (20.9%)</td>
<td>4 (17.4%)</td>
<td>6 (30%)</td>
<td>117 (97.5%)</td>
<td>6 (75%)</td>
</tr>
<tr>
<td>Positive urine Cytology</td>
<td>0 (0%)</td>
<td>2 (4.7%)</td>
<td>0 (0%)</td>
<td>2 (10%)</td>
<td>75 (62.5%)</td>
<td>6 (75%)</td>
</tr>
</tbody>
</table>

* Significant p<0.0001 using a non-parametric test, b Pearson Chi-square test.

a Statistical significance was detected between the 3 studied groups (control, benign, and malignant) regarding sFas and cytology (X2=157, and 75.4, at p<0.0001, respectively).

b Statistical significance was detected between bilharzial benign group (bilharzial dysplasia and bilharzial cystitis) versus bilharzial malignant group (X2=82.4, at p<0.0001). Statistical significance was detected between malignant bilharzial and non-bilharzial group (X2=20.7, at P<0.0001). No statistical difference between bilharzial (bilharzial dysplasia, and bilharzial cystitis) and nonbilharzial benign groups.

Table (3): Combined sensitivity and specificity for investigated parameters in detection of bladder cancer, especially superficial, low-grade cancer.

<table>
<thead>
<tr>
<th>Investigated parameters</th>
<th>Bladder cancer</th>
<th>Superficial bladder cancer</th>
<th>Low grade bladder cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sens.%</td>
<td>Spec.%</td>
<td>Sens.%</td>
</tr>
<tr>
<td>Urinary sFas</td>
<td>97.5</td>
<td>88</td>
<td>97.2</td>
</tr>
<tr>
<td>Urine cytology</td>
<td>62.5</td>
<td>97.6</td>
<td>67</td>
</tr>
<tr>
<td>Urinary sFas+Urine cytology</td>
<td>99.2</td>
<td>88</td>
<td>99.1</td>
</tr>
</tbody>
</table>

Fig. (1): ROC curve analysis for sFas to calculate the best cut-off point to discriminate between malignant and nonmalignant groups. Open circle denotes best cut-off point of sFas (solid line) as 993.4 ng/mg protein (sensitivity = 97.5% and specificity = 96.34%; AUC [SE] = 0.998 [0.007], 95% confidence limits range = 0.962-0.998, p<0.0001).

Discussion

This is the first study to quantify the basal concentration of urinary sFas in bilharzial and non-bilharzial bladder cancer and to establish a cutoff value, which may be of clinical importance in detecting bladder cancer and in evaluating its stage and grade in comparison to urine cytology. The urinary sFAs was assessed in 203 individuals using ELISA technique as a quantitative useful method. Urinary levels of these factors were found to be influenced by hydration status and urine output, so their levels were normalized to urinary protein content (mg) for the accuracy of the test. The normalization to total protein was found to be better than to creatinine because total protein is less influenced by hematuria, a condition commonly found in bladder cancer patients [24]. The performance of the urinary sFAs by ELISA has been evaluated and was reliable for their quantization in minimal amount of voided urine samples. Authors found it is more interesting to evaluate the functional sensitivity, which is preferable for the evaluation of all low-range urinary marker concentrations of clinical relevance, either at initial diagnosis or at follow-up. Our functional sensitivity study was performed in the actual conditions of a routine clinical laboratory: We measured the urine pools using three different calibrator lots. The intra- and inter-assay CVs and the analytical recovery percentage for the investigated urinary marker ranged from 8.9-9.5, and 97.6%-100% as recommended for tumor markers [25].

The diagnostic profile of urinary sFas was evaluated through the ROC curve. Both the positivity rates of sFas were significantly high in
bladder cancer patients as compared to the benign cases while it was not detected in controls. Similarly, the level of sFas in bladder cancer cases was 86.7 and 172.63 folds higher than benign and control individuals, respectively. For benign cases, urinary sFas levels were 25.69 folds higher than control individuals, indicating the usefulness of sFas as a powerful urinary diagnostic marker for bladder cancer. This result confirms the hypothesis that apoptosis-regulating genes play a critical role in carcinogenesis. Fas/FasL system exerts a central role in the apoptosis process and its alterations are noticeable in bladder cancer [14]. Soluble Fas, is expressed and shedded by human transitional bladder carcinoma cell lines. It is generated by alternative mRNA splicing [26,27]. SFas has been identified in the supernatants of several tumour cell lines [28-30]. It does prevent recognition of malignant cells by the immune system [28,31-33].

In the present study, bilharzial status was detected in 133 cases. Of them, 113 were diagnosed as bladder cancer patients while the remaining was with benign urological diseases (n=20). Among the enrolled patients collectively, positive sFas was significantly higher in patients (benign versus malignant) with bilharzial infection as compared with those with no bilharzial infection. Bilharziasis was associating 30% (6/20) and 99.1% (111/112) of positive sFas (993.4ng/mg protein) among the benign cases and the bladder cancer cases, respectively. For the entire groups, significant increment of sFas was reported in bilharzial bladder cancer as compared to non-bilharzial ones (X2=20.7, p<0.0001), however no significant results were reported among benign bilharzial and non-bilharzial patients. Moreover, the current study detected 2 false-positive smears in benign cases with bilharzial dysplastic lesions. The presence of atypical cells in these benign cases may be attributed to morphological alterations in premalignant cells or reactive atypia to bilharzial infestation. In the future, cystoscopies and biopsies will determine whether the positive cytology was false-positive or an indication of early tumor detection.

The relation between positivity rate of sFas and urine cytology with different clinicopathological factors among bladder cancer patients was investigated. The sFas positivity rate was significantly increased with bilharzial infection. This significant association reflects the more aggressive phenotype of this bladder cancer subtype. Similarly, sFas positivity rate increment towards SCC vs TCC was significant. Incidences of bladder neoplasm secondary to bilharziasis, which is frequently associated with the development of SCC, are particularly high in the Nile River Valley. Our results confirm the usefulness of using urinary sFas for diagnosing bilharzial bladder carcinoma either as TCC or SCC. Moreover, sFas positivity rates were increased in cancer patients in a manner directly related to tumor stage and burden, suggesting a potential role for sFas in the biology of malignant disease. When a urine molecular marker is used for diagnostic work-up of bladder cancer, it should have a high sensitivity [34]. As reported in (Table 3), the sensitivity of urinary sFas was superior over urine cytology for early detection of bladder cancer patients with superficial and low grade tumors.

Although further multicentric studies will be required to define the impact of urinary sFas on early detection and disease monitoring before clinical application, also, longitudinal follow-up of bilharzial cases is needed to understand its association in cancer development, our data predict a causal role for sFas in early detection of bilharzial bladder cancer, and this antagonistic, antiapoptotic protein may well become a novel target in both detection and intervention.

Acknowledgment:

This work was supported by the Egyptian Academy of Research and Technology, the Technical development and Scientific Sector. The Science and Technology Center, Project 21/2.

Conflict of interest:
The authors have nothing to disclose.

References


